EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy - EASL | Cliniscan
Cliniscan
Solutions
Tarifs
Ressources
Se connecter
Essayer gratuitement
Cliniscan
Retour aux recommandations
EASL
2026
EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy
Document
Analyser ce document